Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.

MACK

Merrimack Pharmaceuticals (MACK)

Merrimack Pharmaceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:MACK
DatumZeitQuelleÜberschriftSymbolFirma
10/05/202422h45Edgar (US Regulatory)Form 25 - Notification of the removal from listing and registration of matured, redeemed or retired securitiesNASDAQ:MACKMerrimack Pharmaceuticals Inc
10/05/202422h43Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MACKMerrimack Pharmaceuticals Inc
10/05/202422h30Business WireMerrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common StockNASDAQ:MACKMerrimack Pharmaceuticals Inc
09/05/202413h45Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:MACKMerrimack Pharmaceuticals Inc
09/05/202413h43Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MACKMerrimack Pharmaceuticals Inc
09/05/202413h30Business WireMerrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of DissolutionNASDAQ:MACKMerrimack Pharmaceuticals Inc
30/04/202423h15Business WireMerrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of DissolutionNASDAQ:MACKMerrimack Pharmaceuticals Inc
27/03/202421h30Business WireMerrimack Receives $225 Million Milestone Payment from IpsenNASDAQ:MACKMerrimack Pharmaceuticals Inc
07/03/202422h42Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:MACKMerrimack Pharmaceuticals Inc
07/03/202422h39Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MACKMerrimack Pharmaceuticals Inc
07/03/202422h30Business WireMerrimack Reports Full Year 2023 Financial ResultsNASDAQ:MACKMerrimack Pharmaceuticals Inc
07/03/202422h15Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:MACKMerrimack Pharmaceuticals Inc
07/03/202418h29Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MACKMerrimack Pharmaceuticals Inc
05/03/202422h44Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:MACKMerrimack Pharmaceuticals Inc
22/02/202422h46Edgar (US Regulatory)Form SCHEDULE 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:MACKMerrimack Pharmaceuticals Inc
14/02/202422h20Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MACKMerrimack Pharmaceuticals Inc
13/02/202422h26Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:MACKMerrimack Pharmaceuticals Inc
13/02/202422h22Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MACKMerrimack Pharmaceuticals Inc
13/02/202422h18Business WireMerrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)NASDAQ:MACKMerrimack Pharmaceuticals Inc
31/01/202420h08Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:MACKMerrimack Pharmaceuticals Inc
25/01/202422h05Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:MACKMerrimack Pharmaceuticals Inc
28/12/202322h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MACKMerrimack Pharmaceuticals Inc
13/12/202322h05Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:MACKMerrimack Pharmaceuticals Inc
11/12/202322h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MACKMerrimack Pharmaceuticals Inc
21/11/202300h59Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MACKMerrimack Pharmaceuticals Inc
16/11/202323h09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MACKMerrimack Pharmaceuticals Inc
02/11/202321h30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MACKMerrimack Pharmaceuticals Inc
02/11/202321h30Business WireMerrimack Reports Third Quarter 2023 Financial ResultsNASDAQ:MACKMerrimack Pharmaceuticals Inc
14/08/202322h05Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:MACKMerrimack Pharmaceuticals Inc
09/08/202322h06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MACKMerrimack Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:MACK